Two Sigma Advisers
MLYS icon

Two Sigma Advisers’s Mineralys Therapeutics MLYS Stock Holding History

Two Sigma Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-353,700
Closed -$12.8M – 1299
2025
Q4 		$12.8M Buy
+353,700
New +$14.2M 0.03% 468

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Two Sigma Advisers's MLYS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 353,700 shares — an estimated $12.8M sold.

Two Sigma Advisers first reported a position in MLYS in Q4 2025 and held it in 1 quarter. The position peaked at $12.8M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 353,700 Mineralys Therapeutics shares in Q1 2026, an estimated $12.8M.
  • Two Sigma Advisers first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 1 quarter.
  • Two Sigma Advisers's Mineralys Therapeutics position peaked at $12.8M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.